Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EBIT (2019 - 2025)

Historic EBIT for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to -$7.1 million.

  • Biodesix's EBIT rose 1792.57% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.6 million, marking a year-over-year increase of 623.29%. This contributed to the annual value of -$34.5 million for FY2024, which is 1655.46% up from last year.
  • According to the latest figures from Q3 2025, Biodesix's EBIT is -$7.1 million, which was up 1792.57% from -$9.7 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's EBIT ranged from a high of -$5.6 million in Q1 2021 and a low of -$16.4 million during Q1 2023
  • For the 5-year period, Biodesix's EBIT averaged around -$10.2 million, with its median value being -$10.6 million (2021).
  • As far as peak fluctuations go, Biodesix's EBIT crashed by 34021.86% in 2021, and later surged by 5054.0% in 2023.
  • Over the past 5 years, Biodesix's EBIT (Quarter) stood at -$11.7 million in 2021, then fell by 18.93% to -$13.9 million in 2022, then skyrocketed by 50.54% to -$6.9 million in 2023, then increased by 3.22% to -$6.6 million in 2024, then fell by 6.05% to -$7.1 million in 2025.
  • Its last three reported values are -$7.1 million in Q3 2025, -$9.7 million for Q2 2025, and -$9.1 million during Q1 2025.